Phase 4 Osteoarthritis Trial, Recruiting NCT05868330 Sponsor: Melinda Seering Condition: Osteoarthritis
Back to Osteoarthritis

Phase 4 Osteoarthritis Trial, Recruiting

NCT05868330
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are patients of an orthopedics service scheduled to have reverse shoulder replacement surgery
  • People classified as ASA physical status class I, II, or III — a standard medical rating of overall health (confirm with trial site)
  • People aged at least 18 years old but under 90 years old
  • People who are able and willing to give informed consent to participate
  • People whose surgery is planned and non-emergency

Who may not be able to join:

  • People who are unable to cooperate or stay still during the placement of a nerve block procedure
  • People whose medical situation means a regional nerve block is not appropriate — for example, those taking blood-thinning medications
  • People with significant lung disease, or a known allergy to any of the medications used in the nerve block (Exparel, Bupivacaine, or Ropivacaine)
  • People who have nerve damage or a nerve condition in the arm or shoulder that would be targeted by the block
  • People with a documented diagnosis of kidney failure
  • People with a documented diagnosis of liver failure
  • People who are unable or unwilling to give informed consent
  • People who are currently incarcerated
  • People who are pregnant
  • People who are unable to communicate in English
  • People who regularly use opioid pain medications before surgery at a level greater than 20 MME (a standard measure of opioid dosage — confirm with trial site)
  • People whose shoulder condition involves a fracture
  • People who are having revision surgery (a repeat or corrective procedure following a previous surgery)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Melinda Seering, MD, University of Iowa

Phone: 5156895508

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Melinda Seering
Registry
ClinicalTrials.gov
Start date
19 August 2024
Est. completion
1 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pain Score Assessed by functional pain score at POD 1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov